ClinicalTrials.gg
CompletedNCT04315792Updated Sep 23, 2024

Evaluate Efficacy and Safety of Endoxifen in Bipolar I Disorder Patients

A Phase 3 interventional study of Endoxifen and Placebo oral tablet in Bipolar I Disorder, sponsored by Jina Pharmaceuticals Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-09-23.

Sponsored by Jina Pharmaceuticals Inc. · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Jan 2021, 5 years 9 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
124
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The present study aims to evaluate the efficacy and safety of 8 mg endoxifen in the study population. As endoxifen represents a totally new class of drugs in the treatment of the bipolar disorder, it is essential to compare the drug against placebo to rule out the psychological influence upon study results. More so given the risks to patients and their communities from a medication whose efficacy has not been thoroughly evaluated against a placebo control. Thus, Endoxifen will be compared to placebo to demonstrate that the test product is active and to establish that the study is sufficiently sensitive to detect differences between the investigational products.

Read the detailed description

Protein Kinase C (PKC) plays a major role in the regulation of both pre and postsynaptic neurotransmission. Excessive activation of PKC results in symptoms related to bipolar disorder. PKC exists as a family of closely related subspecies, has a heterogeneous distribution in the brain (with particularly high levels in presynaptic nerve terminals), and plays a crucial role in the regulation of neuronal excitability, neurotransmitter release, regulation of synaptic plasticity and various forms of learning and memory. Research findings show that the PKC pathway can be used as a target for developing treatment strategies for bipolar disorder. Endoxifen exhibited activity in inhibiting the PKC activity.

In patients with acute bipolar mania, rapid reduction of symptoms is a key treatment goal; however, there is also a need for effective maintenance of effect treatment beyond the period of acute stabilization. The current study will evaluate the efficacy and safety of Endoxifen in Bipolar I Disorder patients against a control placebo arm.

02

Conditions studied

  • Bipolar I Disorder

Keywords

  • Endoxifen, Bipolar I Disorder
03

In context

Lead sponsor

Jina Pharmaceuticals Inc. is the lead sponsor of 6 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male and female patients, 18 to 65 (both inclusive) years of age willing to give written along with at least one first degree relative (the legally acceptable representative [LAR]) to participate in the study before initiating any study related procedures.
  2. Patients must have a diagnosis of bipolar I disorder and currently display an acute manic episodes with or without mixed features according to criteria as judged by the Investigator.
  3. Young Mania Rating Scale (YMRS) total score of > 20 and ≥4 on two of four core items (irritability, speech, content, disruptive/aggressive behavior) at screening and at randomization (baseline).
  4. Score of >4 in Severity of illness criteria of Clinical Global Impressions- bipolar disorder (CGI-BP) Scale for overall illness at screening and at randomization (baseline).
  5. Ready for voluntary hospitalization (along with the accompanying LAR if required and as advised by the Investigator) for the current manic episode 2 days prior to randomization up to 21 days of in-patient treatment period.
  6. Last intake of the medication(s) for BPD should be 2-7 days prior to randomization depending upon the individual drug's plasma half-life.
  7. Patient and / or LAR understand and agree to comply with all the study requirements.
  8. Male patients of child begetting potential must be practicing adequate .
  9. Females of (which include girls who have entered puberty and all women who have a uterus and ovaries and have not completed menopause), must use anacceptable and effective method of avoiding pregnancy, starting at least four weeks before the first dose of study drug and continuing until at least one month after the last dose of study drug.
  10. Subjects judged clinically not to be at serious suicide risk.

Exclusion criteria

Exclusion Criteria:

  1. Newly diagnosed patients and not having any suitable treatment exposure in the past for their bipolar mood disorder.
  2. > 20% improvement in YMRS total scores between screening and randomization visits.
  3. Patients who meet criteria for any psychiatric disorder other than Bipolar I Disorder with Acute Mania Episode with or without mixed features.
  4. Patients with seizure disorder.
  5. Obsessive compulsive disorder or any other co-morbid Axis I anxiety disorder
  6. Patients with borderline or anti-social personality disorder of sufficient current severity to interfere with conduct of the study
  7. Patients with classical premenopausal symptoms found at risk of developing intolerable hot flushes, irregular vaginal bleeding.
  8. Use of the following medications:

    • Antihypertensive agents if stable dose has not been administered for at least 1 month before randomization
    • Antidepressants in the week (or a period of 5 half-lives of the drug) prior to randomization
    • Continuous daily or standing orders use of benzodiazepines during the month preceding screening (approximately 5 weeks prior to screening)
    • Potent cytochrome P450 (CYP) inducers and CYP2D6/ inhibitors 14 days prior to randomization
    • Depot antipsychotic medications within 1 dosing interval prior to randomization
    • Use of systemic estrogens 6 weeks prior to randomization
    • Patients currently on carbapenem agents
  9. Any of the following laboratory abnormalities

    • Serum ≥ 1.5 times
    • Serum /ALT ≥ 2.5 times ULN
    • Serum TSH >10% above the ULN, regardless of treatment for hypothyroidism or hyperthyroidism
    • Serum triglyceride level > 2.5 times ULN
  10. Patients with the following cardiac conditions are excluded:

    • Recent myocardial infarction (\<12 months)
    • prolongation (screening with QTc >450 msec for men, QTc> 470 msec for women)
    • History of QTc prolongation or using concomitant medications (as judged by the Investigator) which prolong QTc interval
    • Sustained cardiac arrhythmia or history of sustained cardiac arrhythmia
    • De compensatory congestive heart failure
    • Complete left bundle branch block
    • First-degree heart block with PR interval > 0.22 seconds
  11. Presence of a coagulation disorder; active or past history of venous thromboembolism including deep venous thrombosis or pulmonary embolism.
  12. Current prolonged immobilization.
  13. History or current presence of retinal pathology including retinal vein thrombosis
  14. Increased risk of stroke as per the Investigator's discretion.
  15. History of or intolerance to tamoxifen or any other ingredients of the preparation.
  16. Serious, unstable illnesses including hepatic, renal, gastroenterologic, respiratory, cardiovascular (including ischemic heart disease), endocrinologic, neurologic, immunologic, or hematologic disease as per history and medical examination.
  17. Drug screen positive for any drug of abuse at screening (with the exception of benzodiazepines used in therapeutic dose for management of acute mania), active substance abuse in the past 2 months or history of substance dependence (excluding nicotine and caffeine) within 3 months of screening.
  18. History of breast or uterine cancer, or abnormal uterine bleeding.
  19. Current leukopenia or thrombocytopenia as judged by the Investigator in the best health interest of the subject.
  20. suicidal or homicidal ideation.
  21. Participation in a clinical trial of another drug within 30 days prior to screening.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
124 participants (actual)

Study arms

  • Experimental
    Endoxifen Arm

    Endoxifen enteric-coated tablet (8 mg). Patients will continue treatment with their initial randomized medication for 3 weeks

    Drug: Endoxifen

  • Placebo comparator
    Placebo Arm

    Placebo tablets of endoxifen. Patients will continue administration with their initial randomized medication for 3 weeks

    Drug: Placebo oral tablet

Interventions

  • Administration of Endoxifen for 3 weeks

  • DrugPlacebo oral tablet

    Administration of Placebo for 3 weeks

06

What researchers measure

Primary outcomes

  1. Evaluate the efficacy and establish superiority of endoxifen 8 mg against placebo in Bipolar I Disorder patients (Mean change in total YMRS score)

    Mean change in total YMRS score at Day 21 against baseline (in-patient setup)

    Time frame: 3 weeks

Secondary outcomes

  1. Evaluate the safety and tolerability of all the treatments among Bipolar I Disorder patients (treatment related adverse events)

    All treatment related adverse events including abnormal laboratory parameters

    Time frame: 3 weeks

07

Study locations

1 site
  • 16420 NW 59 Avenue
    Miami, Florida 33014, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2020 to primary completion in Jan 2021, 5 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 16, 2020
First posted
Mar 20, 2020
StartActual
Aug 3, 2020
Primary completionActual
Jan 25, 2021
CompletionActual
Aug 25, 2021
Last update
Sep 23, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 23, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04315792
Lead sponsor
Jina Pharmaceuticals Inc.
Collaborators
Novum Pharmaceutical Research Services, Lambda Therapeutic Research Ltd.
Responsible party
Sponsor
First posted
Mar 20, 2020
Start date
Aug 3, 2020
Primary completion
Jan 25, 2021
Completion
Aug 25, 2021
Last update
Sep 23, 2024

Study contacts

Theodore R Treese, MD
principal investigator · Innovative Clinical Research, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Endoxifen

Start the discussion